Cipla, Solar Pharma ink non-exclusive settlement with Takeda on acid-reflux drug
Drugmakers Cipla and Solar Pharma have signed non-exclusive patent license agreements with Takeda Pharmaceutical Firm Restricted, respectively, for ‘Vonoprazan’ for India. The drug is used to deal with acid-related diseases amongst sufferers. Cipla and Solar Pharma will independently commercialise the drug in India below their respective trademark manufacturers. Earlier this month, Torrent Pharma had additionally … Read more